REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients
Por um escritor misterioso
Descrição
REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.
FDA approves supplemental new drug application for Rexulti to
FDA Approves First Drug to Treat Alzheimer's Agitation
Researcher finds help for Alzheimer's-associated agitation with
Rexulti (brexpiprazole) is filed in Japan for Alzheimer's
FDA Approves First Drug to Treat Agitation Symptoms Associated
Rexulti Works for Agitation in Alzheimer's, Despite Risks, Says
Otsuka and Lundbeck Issue Statement on REXULTI for Alzheimer's
REXULTI® (brexpiprazole) For Healthcare Professionals
First FDA Approved Medication for Agitation Associated with
FDA approves first drug to treat agitation symptoms associated
FDA advisors to weigh use of Rexulti for Alzheimer's agitation
FDA Approves First Drug Meant to Ease Alzheimer's-Linked Agitation
These highlights do not include all the information needed to use
FDA rushes approval of dementia drug that quadruples risk of death
de
por adulto (o preço varia de acordo com o tamanho do grupo)
